Author: admin

  • France 24 Deploys QuickLink StudioEdge, StudioCall

    France 24 Deploys QuickLink StudioEdge, StudioCall

    ISSY-LES-MOULINEAUX, France—France 24, the international news and current affairs television network broadcasting in French, English, Arabic and Spanish, has deployed QuickLink’s StudioEdge and StudioCall to improve its remote guest-integration capabilities.

    By integrating QuickLink’s remote guest solutions into its production workflow, the news network improved connection reliability, guest onboarding simplicity and enhanced contribution quality, the company said.

    Continue Reading

  • A recent common cold may nearly halve risk of COVID-19, study suggests

    A recent common cold may nearly halve risk of COVID-19, study suggests

    Jennifer Oosthuizen / CDC

    A study in Israel confirms antibiotic use as a major risk factor for Clostridioides difficile infection (CDI) in hospital patients, particularly for those who don’t carry the bacterium, researchers reported last week in JAMA Network Open.

    For the study, which was conducted from June 2017 through June 2023, researchers analyzed data on patients admitted to a large tertiary medical center in Israel that routinely screens high-risk patients for C difficile carriage. While broad-spectrum antibiotic use is a known risk factor for CDI, the researchers wanted to evaluate the rate of hospital-onset CDI among asymptomatic C difficile carriers compared with noncarriers and assess the role of antibiotic exposure in shaping CDI risk in the two populations.

    Antibiotic exposure linked to double the risk of CDI

    Among 33,756 hospitalizations (median age, 78 years; 52.8% male), 1,624 (4.8%) had a positive screening result for C difficile. Overall, CDI occurred in 67 (4.1%) of 1,624 carriers and 47 (0.1%) of 32,132 noncarriers. 

    In the entire cohort, exposure to any antibiotic was associated with double the risk for CDI (hazard ratio [HR], 1.98; 95% confidence interval [CI], 1.24 to 3.16), with each additional day of antibiotic exposure having an HR of 1.08 (95% CI, 1.03 to 1.13). Beta-lactam/beta-lactamase inhibitor combinations were associated with significantly increased risk, with piperacillin-tazobactam showing the most pronounced hazard for CDI (HR, 2.18; 95% CI, 1.41 to 3.36).

    Although a positive C difficile screening result at admission was associated with a high risk of CDI (HR, 27.5; 95% CI, 18.7 to 40.3), antibiotic exposure among asymptomatic C difficile carriers was not significantly associated with a further increase in CDI risk (HR, 1.07; 95% CI, 0.73 to 1.58).

    The study authors say the findings suggest that, while antibiotic stewardship may reduce CDI risk in noncarriers, additional strategies may be needed for asymptomatic carriers.

    “Among carriers, preventive measures in addition to antibiotic stewardship should be evaluated in hospitalized patients and may include probiotics, monoclonal antibodies, or biotherapies,” they wrote. “However, further research is necessary to evaluate the potential effectiveness of these interventions, their association with microbiome alterations, and potential changes in antimicrobial resistance patterns among patients and within the hospital environment.”

    Continue Reading

  • Daniel Zovatto, Bill Pullman Join Movie Cast

    Daniel Zovatto, Bill Pullman Join Movie Cast

    Paul Schrader‘s next feature, The Basics of Philosophy, is rounding out its cast.

    Daniel Zovatto (Woman of the Hour), Bill Pullman (Lost Highway), Shiloh Fernandez (The Odyssey), Dana Delany (Tulsa King) and Karl Glusman (Nocturnal Animals) have been added to the film, The Hollywood Reporter has learned exclusively. Jack Huston (House of Gucci) and Sofia Boutella (Rebel Moon) were previously reported as stars of the movie that wrapped principal photography late last month.

    The Basics of Philosophy focuses on a repressed philosophy professor (Huston) who has been grappling with lingering guilt over a decision from his past when the victim suddenly returns to his life. The project continues Schrader’s “man in a room” stories that began with his script for Martin Scorsese’s Taxi Driver and have also included the features First Reformed, The Card Counter and Master Gardener that count Schrader as writer and director.

    Schrader helmed The Basics of Philosophy from his own script. Serving as producers are Braxton Pope and David Wulf, who both previously collaborated with Schrader on The Card Counter, which Focus Features released in 2021 following its premiere at the Venice Film Festival. Sean Price Williams (Good Time) served as cinematographer on The Basics of Philosophy for his first project with Schrader.

    “A character I’ve returned to over the years — the taxi driver, a drug dealer and a card player — is now a professor of philosophy,” Schrader says. “His father’s death free-falls him into the past. A similar man wearing a new mask.”

    Adds Pope, “Paul is a singular, original voice in American cinema — creating a new chapter in the book of his creative life with our superb cast has been deeply rewarding.” And Wulf notes, “Schrader’s mastery of the subtlety of characters and experiences drives an authenticity rarely found in modern films — it’s a remarkable feat watching Paul test and transcend generational boundaries and norms tackling troubling issues with ease.”

    After his breakout success with Taxi Driver, Schrader worked on the scripts for such Scorsese projects as Raging Bull, The Last Temptation of Christ and Bringing Out the Dead. Schrader has directed such movies as American Gigolo, Mishima: A Life in Four Chapters and First Reformed, with the script for the latter earning the filmmaker his first Oscar nomination.

    Huston is represented by CAA and 111 Media. Boutella is repped by CAA, Untitled Entertainment and 42 Management & Production. Zovatto is repped by Gersh. Pullman is repped by CAA. Delany is repped by UTA. Fernandez is repped by Untitled Entertainment and Ziffren Brittenham. Glusman is repped by Paradigm and manager Ilene Feldman.

    Continue Reading

  • Compliant Contacts: Hacking Door Locks With Pen Springs

    Compliant Contacts: Hacking Door Locks With Pen Springs

    As you may have guessed given our name, we do love hacks around here, and this one is a great example of making some common, everyday things work in uncommon ways. [Nathan] sent in his hack to detect the door lock position in his basement.

    Having a house that dates back to the 1890s, much of it was not very conducive to using off-the-shelf home automation devices. [Nathan] wanted a way to check the status of the basement deadbolt. He went about putting together a custom sensor using some spare parts, including a spare BeagleBone Black, and some springs from a ballpoint pen. Going full MacGyver, [Nathan] used springs from a ballpoint pen to craft a compliant contact for his sensor.

    The pair of springs sat in the door frame and came in contact with the deadbolt; given they are springs, the exact position of the sensor was not very sensitive, as if too close it would just compress the springs slightly more. The springs were wired to the BeagleBone Black’s GPIO, acting as a switch to sense when there was conductivity between the springs through the deadbolt.

    This wasn’t just a plug-it-in-and-it-works type of project, mind you; the BeagleBone Black was over 15 ft away from the sensors, lending plenty of opportunity for noise to be introduced into the lines. To combat this, [Nathan] created an RC filter to filter out all the high-frequency noise picked up by his sensor. Following the RC filter, he added in some code to handle the debounce of the sensor, as the springs have some inherent noise in them. Thanks [Nathan] for sending in your resourceful hack; we love seeing the resourcefulness of reusing things already on hand for other purposes. Be sure to check out some of the other repurposed components we’ve featured.

    Continue Reading

  • Kelly Clarkson’s Ex-Husband Brandon Blackstock Died or Melanoma

    Kelly Clarkson’s Ex-Husband Brandon Blackstock Died or Melanoma

    The official cause of the death of talent manager Brandon Blackstock, the ex-husband of pop star and daytime television host Kelly Clarkson, was revealed by the local coroner on Monday. 

    Blackstock, who was married to the American Idol winner from 2013-22, was revealed last week to have died of cancer as initial reports about his death came out. On Monday, the Silver Bow County coroner announced that Blackstock died of melanoma, a form of skin cancer that had been present for three years. The professional talent manager died Aug. 7 at age 48. 

    “The cause of death was melanoma; the manner of death was natural,” Silver Bow County Coroner Dan Hollos told The Hollywood Reporter by phone Monday when asked about Blackstock. He reportedly died at home under hospice care surrounded by loved ones.  

    His death was initially announced by Blackstock’s management company, Starstruck, which was founded by his father, in a statement posted to its Instagram account: “Brandon bravely battled cancer for more than three years. He passed away peacefully and was surrounded by family. We thank you for your thoughts and prayers and ask everyone to respect the family’s privacy during this very difficult time.”

    Late on Wednesday, Clarkson had announced to her fans that she was postponing the August dates of her Las Vegas residency, citing that Blackstock “had been ill” as a reason. The vocal and TV mega-talent said that she needed “to be fully present” for their two children, whom they have been co-parenting for years. “While I normally keep my personal life private, this past year, my children’s father has been ill and at this moment, I need to be fully present for them. I am sincerely sorry to everyone who bought tickets to the shows and I so appreciate your grace, kindness and understanding,” she said.

    Leading up to the death of her ex-husband, with whom Clarkson has been co-parenting daughter River and son Remy since their divorce, she had missed the taping of several episodes of her hit eponymous talk show, prompting concern from fans. Clarkson and Blackstock first met at a rehearsal for the Academy of Country Music Awards in May 2006.

    In addition to his children with Clarkson, Blackstock is survived by his two children from a previous marriage and one grandchild.


    Continue Reading

  • Nintendo announces top-selling Nintendo Switch and Switch 2 eShop games for July 2025

    Nintendo announces top-selling Nintendo Switch and Switch 2 eShop games for July 2025

    Nintendo has revealed the best-selling games on the Japanese Nintendo eShop for July 2025, covering both the Nintendo Switch and the Nintendo Switch 2.

    On the Nintendo Switch 2 chart, Donkey Kong Bananza secured the top position. The 3D platformer, featuring Donkey Kong’s latest adventure, proved the most downloaded title of the month.

    It was followed by Tamagotchi Plaza, set in Tamahiko Town on Tamagotchi Planet, which ranked ahead of major releases Mario Kart World and Street Fighter 6 to take second place.

    The remainder of the Nintendo Switch 2 top ten included Fantasy Life i: The Girl Who Steals Time, Nintendo Switch 2 Welcome Tour, Shine Post: Be Your Idol, Super Mario Party Jamboree – Nintendo Switch 2 Edition + Jamboree TV, Rune Factory: Guardians of Azuma Nintendo Switch 2 Edition, and Wild Hearts S.

    For the original Nintendo Switch, Tamagotchi Plaza topped the list, showing strong cross-platform sales performance. Patapon 1 + 2 Replay ranked second, followed by Minecraft in third.

    The rest of the chart featured Powerful Pro Baseball 2024-2025, Clubhouse Games: 51 Worldwide Classics, Animal Crossing: New Horizons, Mario Kart 8 Deluxe, Fantasy Life i: The Girl Who Steals Time, Pokemon Friends, and Super Mario Party Jamboree.

    The results highlight the enduring popularity of long-running Nintendo franchises alongside the strong debut of Tamagotchi Plaza, which outperformed several established titles on both consoles during the month.

    Continue Reading

  • Study: Kidney-transplant recipients benefit from COVID-19 vaccination

    Study: Kidney-transplant recipients benefit from COVID-19 vaccination

    Jennifer Oosthuizen / CDC

    A study in Israel confirms antibiotic use as a major risk factor for Clostridioides difficile infection (CDI) in hospital patients, particularly for those who don’t carry the bacterium, researchers reported last week in JAMA Network Open.

    For the study, which was conducted from June 2017 through June 2023, researchers analyzed data on patients admitted to a large tertiary medical center in Israel that routinely screens high-risk patients for C difficile carriage. While broad-spectrum antibiotic use is a known risk factor for CDI, the researchers wanted to evaluate the rate of hospital-onset CDI among asymptomatic C difficile carriers compared with noncarriers and assess the role of antibiotic exposure in shaping CDI risk in the two populations.

    Antibiotic exposure linked to double the risk of CDI

    Among 33,756 hospitalizations (median age, 78 years; 52.8% male), 1,624 (4.8%) had a positive screening result for C difficile. Overall, CDI occurred in 67 (4.1%) of 1,624 carriers and 47 (0.1%) of 32,132 noncarriers. 

    In the entire cohort, exposure to any antibiotic was associated with double the risk for CDI (hazard ratio [HR], 1.98; 95% confidence interval [CI], 1.24 to 3.16), with each additional day of antibiotic exposure having an HR of 1.08 (95% CI, 1.03 to 1.13). Beta-lactam/beta-lactamase inhibitor combinations were associated with significantly increased risk, with piperacillin-tazobactam showing the most pronounced hazard for CDI (HR, 2.18; 95% CI, 1.41 to 3.36).

    Although a positive C difficile screening result at admission was associated with a high risk of CDI (HR, 27.5; 95% CI, 18.7 to 40.3), antibiotic exposure among asymptomatic C difficile carriers was not significantly associated with a further increase in CDI risk (HR, 1.07; 95% CI, 0.73 to 1.58).

    The study authors say the findings suggest that, while antibiotic stewardship may reduce CDI risk in noncarriers, additional strategies may be needed for asymptomatic carriers.

    “Among carriers, preventive measures in addition to antibiotic stewardship should be evaluated in hospitalized patients and may include probiotics, monoclonal antibodies, or biotherapies,” they wrote. “However, further research is necessary to evaluate the potential effectiveness of these interventions, their association with microbiome alterations, and potential changes in antimicrobial resistance patterns among patients and within the hospital environment.”

    Continue Reading

  • Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer

    Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer

    Cervical Cancer | Image
    Credit: © freshidea
    – stock.adobe.com

    Treatment with sintilimab (Tyvyt) plus anlotinib demonstrated a potential long-term survival benefit in patients with PD-L1–positive, recurrent or metastatic cervical cancer, according to updated findings from a phase 2 trial (ChiCTR1900023015) published in BioMed Central Medicine.

    Findings showed that at a median follow-up of 47.2 months (range, 0.6–52.9) at the July 12, 2024, data cutoff, the regimen (n = 42) produced a median overall survival (OS) of 17.8 months (95% CI, 12.3-36.5). The respective 1-, 2-, and 3-year OS rates were 69.2% (95% CI, 53.4%-83.2%), 43.6% (95% CI, 30.5%-62.3%), and 33.3% (95% CI, 21.4%-51.9%).

    “Our study suggests that sintilimab plus anlotinib exhibits durable antitumor activity and long-term survival benefit in patients with pretreated PD-L1–positive advanced cervical cancer, which might be an alternative treatment option. For patients experiencing progression after sintilimab plus anlotinib, chemotherapy may still be the essential treatment option,” lead study author Jing Liu, MD, of the Department of Gynecology at the Clinical Oncology School of Fujian Medical University in China, and colleagues wrote in a publication of the data.

    Phase 2 Study Design

    This multicenter, single-arm phase 2 trial enrolled patients 18 to 75 years of age with pathologically confirmed recurrent or metastatic cervical cancer who had a PD-L1 combined positive score of at least 1. Eligible patients had experienced disease progression following at least 1 prior systemic therapy or were unable to tolerate chemotherapy. Patients also needed to have an ECOG performance status of 0 or 1.

    All enrolled patients received intravenous sintilimab at 200 mg on day 1 plus oral anlotinib at 10 mg on days 1 through 14 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, death, withdrawal of consent, or initiation of alternative antitumor therapy. Patients who discontinued study treatment due to progression could receive subsequent therapy at the investigator’s discretion.

    The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), OS, and disease control rate.

    Additional Efficacy Findings, Including Data Following Progression

    Responders (n = 23) achieved a median duration of response (DOR) of 13.2 months (95% CI, 8.2-41.8).

    Among the 42 patients enrolled, 13 received subsequent treatment following progression on sintilimab plus anlotinib; the remaining 29 patients did not receive subsequent therapy due to poor performance status, financial constraints, personal decision, or death.

    Among the 13 patients who did receive additional therapy, 10 were evaluable for response.

    Two of these 10 patients achieved complete response (CR) to subsequent therapy, four achieved partial response (PR), and two had stable disease, yielding an second ORR (ORR2) of 46.1% (95% CI, 23.1%-71.8%) and a second disease control rate (DCR2) of 61.5% (95% CI, 31.6%-86.1%) in the 13-patient subgroup. Among the 10 evaluable patients, the ORR2 was 60.0% (95% CI, 26.6%-87.1%) and DCR2 was 80.0% (95% CI, 44.3%-97.2%). Median time to second PFS (PFS2) was 23.6 months (95% CI, 12.5-29.8), with a median interval of 7.5 months (95% CI, 5.8-not reached [NR]) from first to second disease progression.

    In terms of subsequent therapy received by the 13 patients, 8 patients (61.5%) received platinum-based chemotherapy alone or part of a combination. These patients had a median platinum-free interval of 5.5 months (range, 1.4-56.1) prior to starting sintilimab plus anlotinib and 19.0 months (range, 9.2-69.0) before initiating subsequent therapy. Two achieved CR and two achieved PR, translating to an ORR2 of 50.0%. Three patients who received platinum-based chemotherapy as subsequent treatment remained alive and progression-free at the data cutoff, with a median PFS2 of 23.1 months (95% CI, 13.9-NR).

    Five patients received non–platinum-based regimens as subsequent treatment, with two achieving PR (ORR2, 40.0%); all had disease progression by data cutoff. Albumin-bound paclitaxel was administered to 6 patients (46.2%), resulting in two CRs and two PRs (ORR2, 66.7%); 3 remained alive and progression-free. In contrast, among the 7 patients who did not receive albumin-bound paclitaxel, only 2 achieved PR (ORR2, 28.6%), and all had experienced disease progression by data cutoff.

    Immune checkpoint inhibitors (ICIs) were included in the treatment regimen for 6 patients (46.2%), with four achieving PR (ORR2, 66.7%) and 1 maintaining a sustained response without disease progression. Among the seven patients who did not receive ICI, two achieved CR (ORR2, 28.6%), with 2 patients alive and progression-free at the time of the analysis.

    Safety Profile

    Sintilimab plus anlotinib demonstrated a manageable safety profile, with most adverse effects (AEs) being grade 1 or 2 in severity. The most common any-grade AE was hypothyroidism, occurring in 33.3% of patients, with all instances being grade 2. Other frequently reported AEs included increased aspartate aminotransferase levels (21.4%), hypertension (19.0%), palmar-plantar erythrodysesthesia (19.0%), diarrhea (16.7%), increased alanine aminotransferase levels (16.7%), and fistula formation (14.3%).

    Grade 3 hypertension and diarrhea were each reported in 2.4% of patients, while fistula occurred at grade 3 in 7.1%. Any-grade immune-related AEs included hypothyroidism (33.3%), immune pneumonitis (4.8%; 1 grade 3 case), and immune myocarditis (2.4%; 1 grade 3 case). Laboratory abnormalities such as hypertriglyceridemia (14.3%), anemia (11.9%), and hypercholesterolemia (11.9%) were observed but were primarily low-grade.

    Reference

    Liu J, Lan C, Liu T, et al. Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer. BMC Medicine. 2025;23(1). doi:10.1186/s12916-025-04198-5

    Continue Reading

  • Fawad’s ‘Abir Gulaal’ to release worldwide except India

    Fawad’s ‘Abir Gulaal’ to release worldwide except India


    KARACHI:

    After months of buzz, shifting release dates, and political storm clouds, Fawad Khan’s latest Bollywood film ‘Abir Gulaal’ is finally set to hit the screens worldwide, but not in India because of a ban on Pakistani artists.

    As per Biz Asia, the film will release worldwide on August 29, with its big premiere set overseas but not in India. According to another Indian media report, the movie will release in theatres in over 75 countries, including the United States, United Kingdom, Canada, Australia and New Zealand.

    Directed by Aarti S Bagdi, known for Chalti Rahe Zindagi, Abir Gulaal is expected to be a cross-cultural film that highlights the chemistry between Fawad and Vaani. The film is produced by Indian Stories, A Richer Lens, and Aarjay Pictures. It is co-produced by Vivek B Agarwal, Avantika Hari, and Rakesh Sippy.

    Playing the role of a UK-based chef, Fawad appears opposite Bollywood actor Vaani Kapoor. Abir Gulaal will be an addition to the romantic comedy genre. It will mark Fawad’s return to Bollywood after nine years. Lisa Hayden, Ridhi Dogra, Parmeet Sethi and veteran Farida Jalal are also part of the cast.

    Abir Gulaal was originally slated to release on May 9. However, the film remains banned in India. The ban on Pakistani actors was implemented by the Central Board of Film Certification (CBFC) following the Palagham attack in Indian Illegally Occupied Jammu and Kashmir (IIOJK) in April.

    Many trade organisations, including All Indian Cine Workers Association (AICWA) and the Federation of Western lndia Cine Employees (FWICE), also pressed for a ban on Pakistani artists in the Indian film industry.

    Hence, the release of Sardaar JI 3 which starred Pakistani actor Hania Aamir and Abir Gulaal that cast Fawad in lead role were both halted. The film had generated buzz among fans, particularly due to Fawad’s return to the Bollywood scene.

    Fawad made his Bollywood debut in 2014 with Khoobsurat, starring opposite Sonam Kapoor. He went on to appear in Dharma Productions’s Kapoor & Sons and Ae Dil Hai Mushkil, which was his last Indian project before the ban on Pakistani artists in 2016.

    Continue Reading

  • NASA Explores Industry Possibilities to Raise Swift Mission’s Orbit

    NASA Explores Industry Possibilities to Raise Swift Mission’s Orbit

    To drive the development of key space-based capabilities for the United States, NASA is exploring an opportunity to demonstrate technology to raise a spacecraft’s orbit to a higher altitude. Two American companies – Cambrian Works of Reston, Virginia, and Katalyst Space Technologies of Flagstaff, Arizona – will develop concept design studies for a possible orbit boost for the agency’s Neil Gehrels Swift Observatory.

    Since its launch in 2004, NASA’s Swift mission has led the agency’s fleet of space telescopes in investigating changes in the high-energy universe. The spacecraft’s low Earth orbit has been decaying gradually, which happens to most satellites over time. Because of recent increases in the Sun’s activity, however, Swift is experiencing additional atmospheric drag, speeding up its orbital decay. This lowering orbit presents an opportunity for NASA to advance a U.S. industry capability, while potentially extending the science lifetime of the Swift mission. The concept studies will help determine whether extending Swift’s critical scientific capabilities would be more cost-effective than replacing those capabilities with a new observatory.

    “NASA Science is committed to leveraging commercial technologies to find innovative, cost-effective ways to open new capabilities for the future of the American space sector,” said Nicky Fox, associate administrator, Science Mission Directorate, NASA Headquarters in Washington. “To maintain Swift’s role in our portfolio, NASA Science is uniquely positioned to conduct a rare in-space technology demonstration to raise the satellite’s orbit and solidify American leadership in spacecraft servicing.”

    The concept studies are being developed under Phase III awards through NASA’s Small Business Innovation Research (SBIR) Program, managed by the agency’s Space Technology Mission Directorate, to American small businesses from a pool of existing participants. This approach allows NASA to rapidly explore affordable possibilities to boost Swift on a shorter development timeline than would otherwise be possible, given the rapid rate at which Swift’s orbit is decaying.

    At this time NASA does not have plans for an orbit boost mission and could still allow the spacecraft to reenter Earth’s atmosphere, as many satellites do at the end of their lifetimes. NASA is studying a potential Swift boost to support innovation in the American space industry, while gaining a better understanding of the available options, the technical feasibility, and the risks involved.

    NASA will also work with Starfish Space of Seattle, Washington, to analyze the potential of performing a Swift boost using an asset under development on an existing Phase III SBIR award. Starfish is currently developing the Small Spacecraft Propulsion and Inspection Capability (SSPICY) demonstration for NASA, with the primary objective of inspecting multiple U.S.-owned defunct satellites in low Earth orbit.

    “Our SBIR portfolio exists for circumstances like this – where investments in America’s space industry provide NASA and our partners an opportunity to develop mutually beneficial capabilities,” said Clayton Turner, associate administrator, Space Technology Mission Directorate, NASA Headquarters. “Whether we choose to implement the technologies in this circumstance, understanding how to boost a spacecraft’s orbit could prove valuable for future applications.”

    Swift was designed to observe gamma-ray bursts, the universe’s most powerful explosions, and provide information for other NASA and partner telescopes to follow up on these events. Its fast and flexible observations have been instrumental in advancing how scientists study transient events to understand how the universe works. For more than two decades, Swift has led NASA’s missions in providing new insights on these events, together broadening our understanding of everything from exploding stars, stellar flares, and eruptions in active galaxies, to comets and asteroids in our own solar system and high-energy lightning events on Earth.

    “Over its extremely productive lifetime, Swift has been a key player in NASA’s network of space telescopes – directing our fleet to ensure we keep a watchful eye on changes in the universe, both far off and close to home,” said Shawn Domagal-Goldman, acting director, Astrophysics Division, NASA Headquarters. “Now, this long-lived science mission is presenting us with a new opportunity: partnering with U.S. industry to rapidly explore efficient, state-of-the-art solutions that could extend Swift’s transformative work and advance private spacecraft servicing.”

    Cambrian and Katalyst have each been awarded $150,000 under Phase III SBIR contracts for concept design studies. The NASA SBIR program is part of America’s Seed Fund, the nation’s largest source of early-stage, non-dilutive funding for innovative technologies. Through this program, entrepreneurs, startups, and small businesses with less than 500 employees can receive funding and non-monetary support to build, mature, and commercialize their technologies, advancing NASA missions and helping solve important problems facing our country.

    NASA’s Goddard Space Flight Center in Greenbelt, Maryland, manages the Swift mission in collaboration with Penn State, the Los Alamos National Laboratory in New Mexico, and Northrop Grumman Space Systems in Dulles, Virginia. Other partners include the UK Space Agency, University of Leicester and Mullard Space Science Laboratory in the United Kingdom, Brera Observatory in Italy, and the Italian Space Agency. To learn more about the Swift mission, visit:

    https://www.nasa.gov/swift

    -end-

    Alise Fisher / Jasmine Hopkins
    Headquarters, Washington
    202-358-2546 / 321-432-4624
    alise.m.fisher@nasa.gov / jasmine.s.hopkins@nasa.gov

    Continue Reading